I-Innova Medical Group, i-Inc., uhlolo lwempilo yehlabathi kunye nomqalisi woxilongo kunye noyena mvelisi mkhulu wehlabathi kunye nomsasazi wezixhobo zovavanyo lokuqukuqela okusecaleni, uqinisekisile ukuba inkampani ye-SARS-CoV-2 ye-Antigen Tests ifumanisa ukwahluka kwe-Omicron.
Ukuphendula ukuvela kolu tshintsho, amanyathelo karhulumente aqaliswe kule veki aphinde anyanzelisa ukunxiba imaski eNgilani ezivenkileni nakwizithuthi zikawonke-wonke.
Ngelixa abaphandi besebenza ngenkuthalo ukumisela ukusebenza kogonyo kunye ne-boosters ngokuchasene nokwahluka okutsha, uvavanyo olukhawulezayo sisixhobo esibaluleke kakhulu ekulawuleni ngempumelelo ukusasazeka kwale ntsholongwane kunye nokunceda ukugcina uluntu lukhuselekile. U-Innova uye waqinisekisa iimvavanyo zayo ze-Lateral Flow ziyasebenza ekufumaneni i-B.1.1.529 (Omicron) eyahlukileyo.
U-Innova waqala ukuvavanya umahluko emva kokuba upapashwe yi-WHO ekupheleni kukaNovemba kwaye iziphumo zaqinisekiswa kwezinye iilabhoratri.
Izifundo ezininzi zesayensi kunye novavanyo oluqhubekayo lwempilo yoluntu lwezigidi zabantu rhoqo lubonise iimvavanyo ezikhawulezayo ze-antigen sisixhobo esibalulekileyo sokuchonga abantu abosulelayo ngokukhawuleza nangokulinganayo, nokuba bangenazo iimpawu ze-COVID-19, ngeendlela ngokulula akunakwenzeka ngovavanyo olucothayo, olubiza kakhulu, olusekwe elebhu. Oku kubaluleke ngakumbi emva kweengcebiso zokuqala Ukwahluka kweempawu ze-Omicron zinokuba buthathaka kwabanye abantu kunezinye iintlobo.
Ngelixa intsholongwane iqhubeka nokwenza i-genetic ribonucleic acid (“RNA”) ukwenza izinto ezintsha nezinokuthi zisuleleke ngakumbi okanye ziyingozi ngakumbi, uvavanyo lwe-antigen luka-Innova, olufumanisa iiproteni ezininzi kwintsholongwane, lunokuba sisixhobo esisebenzayo ngakumbi ekulawuleni ukusasazeka. kunye nokunciphisa ukunyuka kunezinye iindlela, ezifana novavanyo lwe-PCR.
Xa kudityaniswa nomthamo wemveliso we-Innova owandisiweyo, amandla okubona abanzi ovavanyo lwe-antigen olukhawulezayo lwe-Innova, olusasazwe ngokubanzi ngurhulumente kulo lonke elase-UK kwiimeko ezahlukeneyo zokusebenzisa isithuba esingaphezu konyaka ngoku, gxininisa indima ka-Innova njengeqabane elibalulekileyo. kumazwe nakumashishini ngokufanayo ekuqulatheni iintlobo ezosulelayo ngakumbi.
INTO ONOKUYITHATHA KWELI NQAKU:
- Xa kudityaniswa nomthamo wemveliso we-Innova owandisiweyo, amandla okubona abanzi ovavanyo lwe-antigen olukhawulezayo lwe-Innova, olusasazwe ngokubanzi ngurhulumente kulo lonke elase-UK kwiimeko ezahlukeneyo zokusebenzisa isithuba esingaphezu konyaka ngoku, gxininisa indima ka-Innova njengeqabane elibalulekileyo. kumazwe nakumashishini ngokufanayo ekuqulatheni iintlobo ezosulelayo ngakumbi.
- Ngelixa intsholongwane iqhubeka nokwenza i-genetic ribonucleic acid (“RNA”) ukwenza izinto ezintsha nezinokuthi zisuleleke ngakumbi okanye ziyingozi ngakumbi, uvavanyo lwe-antigen luka-Innova, olufumanisa iiproteni ezininzi kwintsholongwane, lunokuba sisixhobo esisebenzayo ngakumbi ekulawuleni ukusasazeka. kunye nokunciphisa ukunyuka kunezinye iindlela, ezifana novavanyo lwe-PCR.
- Numerous scientific studies as well as ongoing public health screening of millions of people on a regular basis have shown rapid antigen tests are an important tool for identifying infectious people quickly and equitably, even when they may not have symptoms of COVID-19, in ways that simply are not possible with slower, more expensive, lab-based tests.
